McGinty, Emma E.
Stuart, Elizabeth A.
Caleb Alexander, G.
Barry, Colleen L.
Bicket, Mark C.
Rutkow, Lainie
Funding for this research was provided by:
National Institute on Drug Abuse (R01DA044987)
Article History
Received: 18 January 2018
Accepted: 29 January 2018
First Online: 26 February 2018
Ethics approval and consent to participate
: Approval for consent to participate was waived as this mixed-methods study uses secondary data and qualitative interviews with professionals to collect non-sensitive information about their work. This study was approved by the Johns Hopkins Bloomberg School of Public Health Institutional Review Board (reference number IRB00008334).
: Not applicable.
: Dr. Alexander is the chair of the U.S. Food and Drug Administration’s Peripheral and Central Nervous System Advisory Committee, is a paid consultant to IQVIA, serves on the Advisory Board of MesaRx Innovations, holds equity in Monument Analytics, and serves as a member of OptumRx’s P&T Committee. This arrangement has been reviewed and approved by the Johns Hopkins Bloomberg School of Public Health. The other authors have no disclosures to report.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.